Abstract: Hepatitis C virus inhibitors are disclosed having the general formula: wherein R1, R2, R3, R?, B, Y and X are described in the description. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Type:
Grant
Filed:
September 2, 2008
Date of Patent:
March 29, 2011
Assignee:
Bristol-Myers Squibb Company
Inventors:
Xiangdong Alan Wang, Li-Qiang Sun, Sing-Yuen Sit, Ny Sin, Paul Michael Scola, Yan Chen
Abstract: Provision of a commercially advantageous method for producing an intermediate which is important for producing the antibacterial and which has a mother nucleus common to the antibacterial, and intermediates produced by such method. A method for producing a compound represented by formula (VI): which comprises the steps of treating a compound represented by formula (IV): with a base in the presence of a base to produce a compound represented by formula (V): and hydrolyzing this compound; a compound represented by formula (II): a compound represented by formula (Ia): a compound represented by formula (V): and a compound represented by formula (VI).
Abstract: The present invention relates to phosphodiesterase (PDE) type IV selective inhibitors. Processes for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and their use as PDE type IV selective inhibitors are provided. Prepared compounds correspond to structure XIV Formula (XIV).
Abstract: Imidazo ring compounds, (e.g. imidazo[4,5-c]pyridine, imidazo[4,5-c]quinoline, 6,7,8,9-tetrahydro imidazo[4,5-c]quinoline, and imidazo[4,5-c]naphthyridine compounds) having an isoxazole, dihydroisoxazole, or oxadiazole substituent at the 1-position, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
Type:
Grant
Filed:
June 17, 2005
Date of Patent:
March 29, 2011
Assignee:
3M Innovative Properties Company
Inventors:
William H. Moser, Joan T. Moseman, Tushar A. Kshirsagar, Philip D. Heppner
Abstract: The invention relates to 6-amido substituted pyrazolopyridine derivatives of the formula (I) useful as inhibitors of beta-adrenergic receptor kinase 1 (?ARK-1), compositions containing such compounds and their use for the treatment and prevention of chronic heart failure, hypertension, myocardial ischemia and hepatitis C virus (HCV) infections, and for the prevention of opiate addiction.
Type:
Grant
Filed:
December 20, 2007
Date of Patent:
March 22, 2011
Assignee:
Sanofi-Aventis
Inventors:
Henning Steinhagen, Jochen Huber, Kurt Ritter, Bernard Pirard, Kirsten Bjergarde, Marcel Patek, Martin Smrcina, Linli Wei
Abstract: Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds analogues of the formula: wherein R, R2, R5, E, Z1, Z3, Z4, and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds of the invention bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds, which are useful as probes for the localization of C5a receptors.
Type:
Grant
Filed:
October 5, 2005
Date of Patent:
March 15, 2011
Assignee:
Novartis International Pharmaceutical Ltd.
Inventors:
Jun Yuan, Peter Hrnciar, Qin Guo, George D. Maynard
Abstract: This invention provides novel compounds, and pharmaceutically acceptable derivatives thereof, that are useful as caspase inhibitors. These compounds have the general formula I: where R1, R2, and R3 are as described herein, Ring A contains zero to two double bonds, each X is independently selected from nitrogen or carbon, at least one X in Ring A is a nitrogen, Ring A is optionally substituted as described, and may be fused to a saturated or unsaturated five to seven membered ring containing zero to three heteroatoms, and provided that when X3 is a carbon, a substituent on X3 is attached by an atom other than nitrogen.
Type:
Grant
Filed:
January 26, 2009
Date of Patent:
March 15, 2011
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Julian M. C. Golec, Paul S. Charifson, Jean-Damien Charrier, Hayley Marie Binch
Abstract: The present invention relates generally to the field of ligands for nicotinic acetylcholine receptors (nACh receptors), activation of nACh receptors, and the treatment of disease conditions associated with defective or malfunctioning nicotinic acetylcholine receptors, especially of the brain. Further, this invention relates to novel compounds (indazoles and benzothiazoles), which act as ligands for the ?7 nACh receptor subtype, methods of preparing such compounds, compositions containing such compounds, and methods of use thereof.
Type:
Grant
Filed:
November 18, 2008
Date of Patent:
March 8, 2011
Assignee:
Memory Pharmaceuticals Corporation
Inventors:
Wenge Xie, Brian Herbert, Jianguo Ma, Truc Minh Nguyen, Richard Schumacher, Carla Maria Gauss, Ashok Tehim
Abstract: The present invention provides process for synthesis of 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and 8A,9-dihydro-4aH-isothiazolo[5,4-b]quinoline-3,4-diones of the Formula A. The substituents R, R5, R6, R7, R8 and R9 are defined herein. The invention also provides novel synthetic intermediates useful in the synthesis of 8-methoxy-9H-isothiazolo[5,4-b]quinoline-3,4-diones and 8A,9-dihydro-4aH-isothiazolo[5,4-b]quinoline-3,4-diones.
Type:
Grant
Filed:
August 16, 2007
Date of Patent:
March 8, 2011
Assignee:
Achillion Pharmaceuticals, Inc.
Inventors:
Barton James Bradbury, Jason Allan Wiles, Akihiro Hashimoto, Qiuping Wang, Edlaine Lucien, Godwin Pais, Ha Young Kim
Abstract: Novel compounds of the formula (I), in which D, W, X, Y, T and R1 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.
Type:
Grant
Filed:
July 12, 2002
Date of Patent:
March 8, 2011
Assignee:
Merck Patent GmbH
Inventors:
Dieter Dorsch, Bertram Cezanne, Christos Tsaklakidis, Werner Mederski, Johannes Gleitz, Christopher Barnes
Abstract: 3-(1-Aminocycloalkyl)pyrrolidinyl-substituted-6-dehalodeno(hydrogen-substituted)quinolon carboxylic acid derivatives having specific substituents as represented by the following formula (I), its salts, and hydrates thereof exhibit a broad and potent antibacterial activity on gram-negative and gram-positive bacteria, in particular, resistant bacteria typified by gram-positive cocci, including MRSA, PRSP and VRE. Thus these compounds are usable as drugs.
Abstract: The present invention relates to novel substituted quinoline derivatives according to the general Formula (Ia) or the general Formula (Ib) the pharmaceutically acceptable acid or base addition salts thereof, the quaternary amines thereof, the stereochemically isomeric forms thereof the tautomeric forms thereof and the N-oxide forms thereof. The claimed compounds are useful for the treatment of mycobacterial diseases. In particular, compounds are claimed in which, independently from each other, R1 is halo; p=1; R2 is optionally substituted alkyloxy, alkyl, Ar, Het, or a radical of formula R3 is optionally substituted Ar or Het; q=1, R4 and R5 each independently are alkyl; R6 is hydrogen or a radical of formula r is equal to 0 or 1 and R7 is hydrogen or Ar.
Type:
Grant
Filed:
January 21, 2005
Date of Patent:
March 8, 2011
Assignee:
Janssen Pharmaceutica NV
Inventors:
Jérôme Emile Georges Guillemont, Elisabeth Therese Jeanne Pasquier, David Francis Alain Lancois
Abstract: The invention provides 8-azabicyclo[3.2.1]octyl-2-hydroxybenzamide compounds of formula (I): wherein R2, R7, and m are defined in the specification, or a pharmaceutically -acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
August 26, 2008
Date of Patent:
March 8, 2011
Assignee:
Theravance, Inc,
Inventors:
Daisuke Roland Saito, Daniel D. Long, Priscilla Van Dyke, Timothy J. Church, Lan Jiang, Bryan Frieman
Abstract: The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes.
Type:
Grant
Filed:
July 28, 2008
Date of Patent:
March 8, 2011
Assignee:
Janssen Pharmaceutica NV.
Inventors:
Mark J. Macielag, Michele A. Weidner-Wells, Shu-Chen Lin
Abstract: The invention provides novel 8-azabicyclo[3.2.1]octane compounds of formula (I): wherein R1, R2, R3, and a are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.
Type:
Grant
Filed:
August 26, 2008
Date of Patent:
March 8, 2011
Assignee:
Theravance, Inc.
Inventors:
Daniel D. Long, Daisuke Roland Saito, Priscilla Van Dyke, Lan Jiang, Tmothy J. Church, John R. Jacobsen
Abstract: The invention relates to a process for the preparation of 13,14-dihydro-PGF2? derivatives of R or S configuration at carbon 15, represented by the general formula (I), wherein the identity of the substituents is defined in the description. Compounds of the formula (I) are valuable biologically-active substances or intermediates in the preparation thereof. The invention especially relates to the process for preparation of 13,14-dihydro-15(R)-17-substituted-18,19,20-trinor-PGF2?, i.e., latanoprost.
Type:
Grant
Filed:
October 18, 2007
Date of Patent:
March 1, 2011
Assignee:
Instytut Farmaceutyczny
Inventors:
Jacek Martynow, Julita Szyc, Wieslaw Szelejewski, Osman Achmatowicz, Andrzej Kutner, Krzysztof Wiśniewski, Jerzy Winiarski, Oliwia Zegrocka-Stendel, Piotr Golebiewski
Abstract: The present invention is related to a compound of formula (I) wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R4, p, r and are as defined herein, its preparation, pharmaceutical composition and use as a modulator of the activity of the 11?-hydroxysteroid dehydrogenase type 1 (11?HSD1).
Type:
Grant
Filed:
December 11, 2008
Date of Patent:
March 1, 2011
Assignee:
Sanofi-Aventis
Inventors:
Michel Aletru, Alain Jean Braun, Claudie Namane, Olivier Venier, Christophe Philippo, Patrick Mougenot, Eric Nicolai, Stefan Gussregen
Abstract: Imidazo ring compounds (e.g., imidazoquinolines, 6,7,8,9-tetrahydroimidazoquinolines, imidazonaphthyridines, and imidazopyridines) with an oxime substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
Type:
Grant
Filed:
November 12, 2004
Date of Patent:
March 1, 2011
Assignee:
3M Innovative Properties Company
Inventors:
Tushar A. Kshirsagar, Gregory D. Lundquist, David T. Amos, Joseph F. Dellaria, Jr., Bernhard M. Zimmermann, Philip D. Heppner
Abstract: Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy or hydroxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.
Type:
Grant
Filed:
August 27, 2004
Date of Patent:
March 1, 2011
Assignee:
3M Innovative Properties Company
Inventors:
Kyle J. Lindstrom, Hugues M. H. Martin, Bryon A. Merrill, Michael J. Rice, Joshua R. Wurst, Chad A. Haraldson, Tushar A. Kshirsagar, Philip D. Heppner, Shri Niwas, George W. Griesgraber, Matthew R. Radmer
Abstract: Imidazonaphthyridine ring systems substituted with an aryl substituent, pharmaceutical compositions containing the compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.
Type:
Grant
Filed:
June 17, 2005
Date of Patent:
March 1, 2011
Assignee:
3M Innovative Properties Company
Inventors:
Shri Niwas, Bryon A. Merrill, Philip D. Heppner, Tushar A. Kshirsagar, Gregory D. Lundquist, Jr., David T. Amos, Kyle J. Lindstrom